Sarepta (SRPT) Soars 15% on Bullish Rating

We recently published 10 Big Names Leading Wall Street Gains. Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best-performing stocks on Wednesday.

Sarepta saw its share price jump by 15.25 percent on Wednesday to close at $18.67 apiece as investors took heart from an investment company’s bullish rating for its stock.

In a market note, Mizuho Securities raised its rating for Sarepta Therapeutics Inc. (NASDAQ:SRPT) to “outperform” from “neutral” while raising its price target by 36.8 percent to $26 from $19 previously. The new figure marked a 39 percent upside potential from its latest closing price.

Sarepta (SRPT) Soars 15% on Bullish Rating

Mizuho said the upgrade was based on its confidence in the Elevidys drug—a prescription therapy to treat over four-year-old patients with Duchenne muscular dystrophy—having raked in $131.5 million in sales in just the third quarter, and well ahead of its $50 million target, despite reports of deaths linked to the drug.

Meanwhile, Sarepta Therapeutics Inc. (NASDAQ:SRPT) swung to a net loss of $180 million in the period July to September, reversing a $33.6 million net income in the same period last year.

Revenues dropped by 14.5 percent to $399 million from $467 million year-on-year, amid lower revenues from Elevidys as a result of the shipping suspension in June 2025 due to the death reports.

While we acknowledge the risk and potential of SRPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SRPT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.